Back to News
Market Impact: 0.25
Cantor Fitzgerald Initiates Coverage of Arcutis Biotherapeutics at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Cantor Fitzgerald initiated coverage of Arcutis Biotherapeutics with an Overweight recommendation on October 15, 2026. Arcutis closed at $29.09 that day, up from $26.41 on October 14; the article does not establish that the initiation caused the increase.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ARQT0.45
More News
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- We're downgrading this retail stock after a big comeback. Plus, AI names slide again
- Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher
- Why is Snowflake stock tumbling today?
- The drumbeat to buy battered shares of CoreWeave is growing louder on Wall Street
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can Hedge Funds Use ChatGPT? A Control Framework
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash